SCHEMBL22491528

SCHEMBL22491528

COC(=O)c1cc(O)c2c(c1)NC(=O)CC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 2/20 0.49
▸ LMNA P02545 4/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ XDH P47989 2/20 0.49
▸ TDP1 Q9NUW8 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ NFKB1 P19838 1/20 0.49
▸ GFER P55789 1/20 0.49
▸ NFKB2 Q00653 1/20 0.49
▸ RELA Q04206 1/20 0.49
▸ FUT7 Q11130 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.47
▸ ALOX15 P16050 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ CA12 O43570 2/20 0.42
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29734620 1.00 CRBN (0.49) CRBNLMNAKDM4EXDHTDP1
SCHEMBL22491481 0.84 CRBN (0.48) CRBNLMNAKDM4EPOLBALDH1A1
SCHEMBL29734435 0.84 CRBN (0.48) CRBNLMNAKDM4EPOLBALDH1A1
SCHEMBL22491512 0.78 CRBN (0.43) CRBNLMNAKDM4EALDH1A1ALOX15
SCHEMBL28459022 0.75 LMNA (0.48) CRBNLMNAKDM4EXDHTDP1
SCHEMBL29754229 0.75 CRBN (0.64) CRBNLMNAKDM4EALDH1A1ALOX15
SCHEMBL2497788 0.75 CRBN (0.64) CRBNLMNAKDM4EALDH1A1ALOX15
SCHEMBL22311512 0.74 PDE3B (0.37) CRBNLMNAALDH1A1CA9MEN1
SCHEMBL22938423 0.73 LMNA (0.47) CRBNLMNAKDM4EXDHTDP1
SCHEMBL6352617 0.73 ALDH1A1 (0.47) CRBNLMNAKDM4EXDHTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11420961-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2022-08-23 — — US disclosed
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 — — EP disclosed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 — — US disclosed
EP-3717477-A1 NEW HETEROCYCLIC COMPOUNDS H. Hoffnabb-La Roche Ag (CH) 2020-10-07 — — EP disclosed
CN-111386269-A Novel heterocyclic compound 豪夫迈·罗氏有限公司 2020-07-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420961-B2 Heterocyclic compounds LPXN, MLX, CCNY CRBN 206/4885LMNA 16/4885KDM4E 1597/4885
US-20200392125-A1 HETEROCYCLIC COMPOUNDS LPXN, MLX, CCNY CRBN 206/4885LMNA 16/4885KDM4E 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback